• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV 持续性和治愈研究的建模。

Modeling HIV persistence and cure studies.

机构信息

Program for Evolutionary Dynamics, Harvard University, Cambridge, Massachusetts, USA.

出版信息

Curr Opin HIV AIDS. 2018 Sep;13(5):428-434. doi: 10.1097/COH.0000000000000490.

DOI:10.1097/COH.0000000000000490
PMID:29916846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6112843/
Abstract

PURPOSE OF REVIEW

To provide a summary of the contributions of mathematical modeling to understanding of HIV persistence during antiretroviral therapy.

RECENT FINDINGS

Although HIV persistence during therapy could be caused by continual viral replication or slow-decaying latent infection, most evidence points toward the latter mechanism. The latent reservoir is maintained by a balance of cell death, proliferation, and reactivation, and new methods to estimate the relative contributions of these rates use a wide range of experimental data. This has led to new quantitative predictions about the potential benefit of therapies such as latency-reversing agents or antiproliferative drugs.

SUMMARY

Results of these mathematical modeling studies can be used to design and interpret future trials of new therapies targeting HIV persistence.

摘要

目的综述

总结数学建模在理解抗逆转录病毒治疗期间 HIV 持续存在方面的贡献。

最近的发现

尽管治疗期间 HIV 的持续存在可能是由持续的病毒复制或缓慢衰减的潜伏感染引起的,但大多数证据指向后者的机制。潜伏库是通过细胞死亡、增殖和再激活的平衡来维持的,而使用广泛的实验数据来估计这些速率的相对贡献的新方法。这导致了关于潜伏逆转剂或抗增殖药物等治疗方法潜在益处的新的定量预测。

总结

这些数学建模研究的结果可用于设计和解释针对 HIV 持续存在的新治疗方法的未来试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a7a/6112843/eaec8bb4f008/cohiv-13-428-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a7a/6112843/eaec8bb4f008/cohiv-13-428-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a7a/6112843/eaec8bb4f008/cohiv-13-428-g001.jpg

相似文献

1
Modeling HIV persistence and cure studies.HIV 持续性和治愈研究的建模。
Curr Opin HIV AIDS. 2018 Sep;13(5):428-434. doi: 10.1097/COH.0000000000000490.
2
New Insights into HIV-1 Persistence in Sanctuary Sites During Antiretroviral Therapy.抗逆转录病毒治疗期间HIV-1在庇护所部位持续存在的新见解
AIDS Rev. 2016 Jan-Mar;18(1):55.
3
Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.长期接受抗逆转录病毒治疗的儿科患者中,1型人类免疫缺陷病毒潜伏库中野生型病毒的持续存在及缺乏时间结构。
J Virol. 2002 Sep;76(18):9481-92. doi: 10.1128/jvi.76.18.9481-9492.2002.
4
As good as it gets? The problem of HIV persistence despite antiretroviral drugs.尽管有抗逆转录病毒药物,但 HIV 仍持续存在的问题。
Cell Host Microbe. 2012 Aug 16;12(2):132-8. doi: 10.1016/j.chom.2012.07.005.
5
Therapeutics for HIV-1 reactivation from latency.HIV-1 潜伏激活的治疗方法。
Curr Opin Virol. 2013 Aug;3(4):394-401. doi: 10.1016/j.coviro.2013.06.001. Epub 2013 Jun 28.
6
Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.不同 ART 方案治疗的感染者体内 HIV 标志物的差异:对病毒储存库持续存在的影响。
Viruses. 2020 Apr 27;12(5):489. doi: 10.3390/v12050489.
7
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.HIV-1储存库:在抗病毒免疫反应和抗逆转录病毒疗法存在的情况下病毒持续存在的机制
Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665.
8
HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.病毒血症控制者中 HIV 前病毒负荷、遗传多样性和动力学,随后启动了抑制性抗逆转录病毒治疗。
mBio. 2021 Dec 21;12(6):e0249021. doi: 10.1128/mBio.02490-21. Epub 2021 Nov 16.
9
Current views on HIV-1 latency, persistence, and cure.关于人类免疫缺陷病毒1型(HIV-1)潜伏、持续存在及治愈的当前观点。
Folia Microbiol (Praha). 2017 Jan;62(1):73-87. doi: 10.1007/s12223-016-0474-7. Epub 2016 Oct 5.
10
In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.帕比司他对细胞相关HIV RNA和DNA水平及潜伏性HIV感染影响的体内分析。
Retrovirology. 2016 May 21;13(1):36. doi: 10.1186/s12977-016-0268-7.

引用本文的文献

1
A mathematical study on the drug resistant virus emergence with HIV/AIDS treatment cases.一项关于艾滋病治疗病例中耐药病毒出现情况的数学研究。
Heliyon. 2021 Jan 9;7(1):e05883. doi: 10.1016/j.heliyon.2020.e05883. eCollection 2021 Jan.
2
Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection.潜伏储库中预先存在的耐药性可能会影响慢性 HIV-1 感染期间的 VRC01 治疗效果。
PLoS Comput Biol. 2020 Nov 30;16(11):e1008434. doi: 10.1371/journal.pcbi.1008434. eCollection 2020 Nov.
3
Insight into treatment of HIV infection from viral dynamics models.

本文引用的文献

1
A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation.在抗逆转录病毒治疗期间,大多数 HIV 持续存在是由于受感染细胞的增殖。
Nat Commun. 2018 Nov 16;9(1):4811. doi: 10.1038/s41467-018-06843-5.
2
Ongoing HIV Replication During ART Reconsidered.抗逆转录病毒治疗期间持续的HIV复制再探讨。
Open Forum Infect Dis. 2017 Sep 19;4(3):ofx173. doi: 10.1093/ofid/ofx173. eCollection 2017 Summer.
3
TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.
从病毒动力学模型看 HIV 感染的治疗。
Immunol Rev. 2018 Sep;285(1):9-25. doi: 10.1111/imr.12698.
TLR7 激动剂可诱导 SIV 感染的恒河猴在抗逆转录病毒治疗时短暂的病毒血症,并减少病毒储存库。
Sci Transl Med. 2018 May 2;10(439). doi: 10.1126/scitranslmed.aao4521.
4
Increased T cell trafficking as adjunct therapy for HIV-1.辅助治疗 HIV-1 的 T 细胞趋化
PLoS Comput Biol. 2018 Mar 2;14(3):e1006028. doi: 10.1371/journal.pcbi.1006028. eCollection 2018 Mar.
5
HIV evolution and diversity in ART-treated patients.抗逆转录病毒治疗患者中的 HIV 进化和多样性。
Retrovirology. 2018 Jan 30;15(1):14. doi: 10.1186/s12977-018-0395-4.
6
Re-evaluating evolution in the HIV reservoir.重新评估HIV病毒库中的进化情况。
Nature. 2017 Nov 22;551(7681):E6-E9. doi: 10.1038/nature24634.
7
Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.评估猿猴免疫缺陷病毒/人类免疫缺陷病毒从潜伏期重新激活期间的初始病毒水平。
J Virol. 2018 Jan 2;92(2). doi: 10.1128/JVI.01667-17. Print 2018 Jan 15.
8
Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?HIV抗潜伏期治疗建模:无抗逆转录病毒疗法的HIV缓解的最佳持续时间是多少?
J Virol. 2017 Nov 30;91(24). doi: 10.1128/JVI.01395-17. Print 2017 Dec 15.
9
No evidence of HIV replication in children on antiretroviral therapy.接受抗逆转录病毒治疗的儿童未出现HIV复制迹象。
J Clin Invest. 2017 Oct 2;127(10):3827-3834. doi: 10.1172/JCI94582. Epub 2017 Sep 11.
10
Anti-proliferative therapy for HIV cure: a compound interest approach.抗 HIV 增殖治疗:复利方法。
Sci Rep. 2017 Jun 21;7(1):4011. doi: 10.1038/s41598-017-04160-3.